Reston, Virginia — HealthTalk A.I., a leading patient engagement company, today announced that its first performance evaluation by KLAS found that 100% of its customers are highly satisfied and would purchase again.
The KLAS Emerging Technology Spotlight report provides a first look at customers’ experiences with the HealthTalk A.I. platform and helps other provider organizations separate fact from fiction related to the company’s technology, service, and overall level of customer satisfaction.
In April of 2022, KLAS began interviewing HealthTalk A.I. customers and their results found that HealthTalk A.I. scored an A or A+ for each key performance measure, including:
Supports integration goals
Product has needed functionality
Likely to recommend
The majority of respondents reported that they began seeing results within weeks, and other key strengths noted included:
Improved efficiency with patient communications
Supportive vendor relationship and proactive customer service
Lack of nickel-and-diming
As part of the report, HCIT market research and analysis expert Mike Davis highlighted many of the platform’s benefits, including improved patient engagement, clinical efficiency, and patient satisfaction. He also pointed out the solution’s long-term viability and stated that “these capabilities differentiate the solution and ensure its competitive position in the market.”
“We’re thrilled to have received such high marks from our customers,” said Jerrod Ullah, CEO and founder of HealthTalk A.I. “We strive every day to help each of them advance their mission to assist and empower patients in need.”
If you are a provider, you can access the full KLAS report here.
KLAS is a data-driven company that collects insights on software, services and medical equipment to deliver reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly reflects the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more, visit klasresearch.com.